G1 Therapeutics

123 articles with G1 Therapeutics

• G1 Therapeutics Provides Third Quarter 2020 Corporate and Financial Update

  11/4/2020

  New Drug Application (NDA) for trilaciclib in small cell lung cancer accepted for Priority Review with a PDUFA action date of February 15, 2021

• G1 Therapeutics to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020

  10/28/2020

  G1 Therapeutics, Inc., a clinical-stage oncology company, announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2020 on Wednesday, November 4, 2020 at 4:30 p.m. ET.

• G1 Therapeutics to Present Data on Trilaciclib at North America Conference on Lung Cancer (NACLC)

  10/15/2020

  G1 Therapeutics, Inc., a clinical-stage oncology company, announced that four presentations highlighting the myelopreservation benefits of trilaciclib and its ability to reduce the need for reactive interventions will be featured at the North America Conference on Lung Cancer being held October 16-17.

• G1 Therapeutics Announces Chief Executive Officer Succession Plan

  9/30/2020

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a company whose mission is to deliver innovative therapies that improve the lives of people with cancer, today announced that effective January 1, 2021, Mark Velleca, M.D. Ph.D., will transition to the role of senior advisor and continue to serve as a member of the G1 Board of Directors.

• G1 Therapeutics to Present Data on Oral CDK4/6 Inhibitor Lerociclib at European Society for Medical Oncology (ESMO) Virtual 2020 Congress

  9/14/2020

  - G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that two presentations highlighting data on the investigational oral CDK4/6 inhibitor lerociclib, including updated findings from a Phase 2 trial of lerociclib in combination with fulvestrant in HR+, HER2- advanced breast cancer patients, will be featured at the ESMO Virtual 2020 Congress being held from September 19-21. G1 abstract tit

• G1 Therapeutics to Participate in Four Investor Conferences in September 2020

  9/2/2020

  G1 Therapeutics, Inc., a clinical-stage oncology company, announced that the company will participate in the following investor conferences in September 2020:

• G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer

  8/17/2020

  Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robust myelopreservation benefits

• G1 Therapeutics Provides Second Quarter 2020 Corporate and Financial Update

  8/5/2020

  Partnership for trilaciclib in China and global out-licensing of lerociclib net a combined $40 million in upfront payments, up to $486 million in milestone payments, plus potential royalties

• G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August 2020

  8/4/2020

  G1 Therapeutics, Inc., a clinical-stage oncology company, announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present company updates at two investor conferences in August 2020

• G1 Therapeutics and Simcere Announce Exclusive License Agreement for Trilaciclib in Greater China

  8/3/2020

  Simcere to lead clinical development, regulatory submissions and commercialization of trilaciclib across all indications in Greater China

• G1 Therapeutics to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020

  7/29/2020

  G1 Therapeutics, Inc., a clinical-stage oncology company, announced that it will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2020 on Wednesday, August 5, 2020 at 5:00 p.m. ET.

• G1 Therapeutics Announces License Agreement for Lerociclib

  7/22/2020

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced a license agreement for lerociclib to EQRx™, a biopharmaceutical company focused on making innovative medicines at dramatically lower prices for the benefit of people and society.

• G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico

  6/30/2020

  G1 Therapeutics, Inc. (Nasdaq: GTHX) and Boehringer Ingelheim today announced that the companies have entered into a co-promotion agreement for trilaciclib in the United States and Puerto Rico.

• G1 Therapeutics and Genor Biopharma Announce Exclusive License Agreement for Lerociclib in Asia-Pacific Region

  6/22/2020

  G1 Therapeutics, Inc. and Genor Biopharma Co. Inc. announced an exclusive license agreement for the development and commercialization of lerociclib in the Asia-Pacific region.

• G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital- Non-dilutive capital to support commercialization and additional development of trilaciclib

  6/1/2020

  G1 Therapeutics, Inc., a clinical-stage oncology company, announced that the company has entered into a debt financing agreement with Hercules Capital, Inc. for up to $100 million.

• G1 Therapeutics to Present Data Showing Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer at the ASCO20 Virtual Scientific Program

  5/13/2020

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that data across three randomized, double-blind, placebo-controlled Phase 2 trials of the investigational therapy trilaciclib in small cell lung cancer (SCLC) will be presented on May 29 at the ASCO20 Virtual Scientific Program of the American Society of Clinical Oncology (ASCO)

• G1 Therapeutics Provides First Quarter 2020 Corporate and Financial Update

  5/6/2020

  G1 Therapeutics, Inc., a clinical-stage oncology company, provided a corporate and financial update for the first quarter ended March 31, 2020.

• G1 Therapeutics to Provide First Quarter 2020 Corporate and Financial Update on May 6, 2020

  4/29/2020

  G1 Therapeutics, Inc., a clinical-stage oncology company, announced that it will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2020 on Wednesday, May 6, 2020 at 4:30 p.m. ET.

• G1 Therapeutics to Present at 19th Annual Needham Virtual Healthcare Conference on April 14, 2020

  4/7/2020

  G1 Therapeutics, Inc. announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company update at the 19th Annual Needham Virtual Healthcare Conference on April 14, 2020 at 2:10 p.m. ET.

• G1 Therapeutics Announces Appointment of New Board Member and Chief Commercial Officer

  3/12/2020

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointments of Jack Bailey to its Board of Directors and Soma Gupta as its Chief Commercial Officer (CCO)